Steady Progress in Driving Growth and Improving Profitability
TORONTO, Dec. 14 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS;
NYSE: MDZ), a company providing a range of enabling products and
services to the global life sciences markets, today reported its
fourth quarter and full year results. MDS reported operating
performance improvements across its business units and made
significant progress in executing on its strategy to focus the
Company on the high growth life sciences markets. The Company
delivered on its commitment to divest its interest in Source
Medical, entered into discussions to sell its interest in Calgary
Laboratory Services, and has dramatically reduced the size of
corporate headquarters and removed layers of management through a
700 person workforce reduction. "We are making great progress in
executing on our strategy to enhance performance through better
market focus, execution and productivity improvements. We move into
2006 with positive revenue momentum and a more streamlined cost
structure - one that positions us well to compete in the global
life sciences markets," said Stephen P. DeFalco, President and CEO,
MDS Inc. Fourth Quarter Highlights - Life Sciences year-over-year
currency-adjusted revenue growth of 8% (+ 3% as reported) - Health
(Diagnostics) adjusted EBITDA margin expanded to 26%, up 660 basis
points versus the fourth quarter last year - Consolidated adjusted
EBITDA margin of 17%, up 280 basis points sequentially, on adjusted
EBITDA of $68 million - Restructuring and other charges of $83
million - Adjusted earnings per share of $0.25 - Quarterly cash
dividend of $0.0325 Adjusted EBITDA and adjusted earnings per share
are non-GAAP measures as detailed in the Company's management
discussion and analysis of operating results and financial
position. For the quarter, MDS's consolidated revenue was $390
million, up 8% currency-adjusted (+ 4% as reported) year-over-year.
Adjusted EBITDA was $68 million compared to $54 million in the
third quarter and $70 million in the same quarter last year,
impacted principally by US currency and elevated SG&A expenses.
Adjusted earnings per share were $0.25 compared to $0.16 in the
third quarter and $0.30 in the same quarter last year.
Restructuring and other charges in the quarter were $83 million.
MDS paid a quarterly cash dividend of $0.0325 per share. In the
fourth quarter, the weakness of US currency impacted revenues in
our Life Sciences segment by $16 million, adjusted EBITDA by $9
million and earnings per share by $0.04 per share. In the fourth
quarter, the Company benefited from favorable exchange hedges that
served to offset some of the impact of US currency on the operating
performance. MDS's hedge portfolio in 2006 will not offer the same
benefit as it did in 2004 and 2005. For the full year, revenue was
$1,489 million, up 1% over the prior year. The adjusted EBITDA
margin was 16% on an adjusted EBITDA of $241 million compared to
$306 million in the prior year - impacted principally by US
currency. Adjusted earnings per share were $0.82 compared to $1.10
in fiscal 2004. Consolidated and Health segment results reflect the
reclassification of Source Medical and Calgary Laboratory Services
into discontinued operations. Life Sciences In the quarter, revenue
from the Life Sciences segment was $304 million, up 8%
currency-adjusted (+ 3% as reported) over the same quarter last
year. The adjusted EBITDA margin was 15%, on adjusted EBITDA of $46
million. For the full year Life Sciences revenue was $1,154
million, up 1% over the prior year. Highlights from the quarter
include the following: - Revenue from pharmaceutical research
services revenue was $135 million, up 3% currency-adjusted (- 2% as
reported). Backlog was up 13% year-over-year and 8% sequentially to
US$340 million. - Isotopes revenue was $96 million, up 6%
currency-adjusted (- 1% as reported) compared to the same quarter
last year. Cobalt shipments increased by approximately 15% in the
fourth quarter compared to prior year. TheraSphere(R), our
innovative treatment for liver cancer, became eligible for sale in
Europe and Bexxar became available in Canada. - Analytical
instruments revenue was $73 million, up 23% currency- adjusted (+
20% as reported) compared to the same quarter last year. The
Company introduced two new products, the CellKey(TM) System and
Tempo(TM) Liquid Chromatography systems. Our analytical instruments
business received two awards; the AME Award for Manufacturing
Excellence and the 2005 Frost & Sullivan Award for Drug
Discovery Technologies Product Innovation. Health Health segment
revenue in the fourth quarter, which now only includes the
Company's Canadian diagnostics business, was $86 million, up 9%
year-over- year. Adjusted EBITDA grew 47% to $22 million compared
to $15 million in the same period last year. For the full year,
revenue was $335 million. Highlights from the quarter include the
following: - MDS Diagnostics continued their focus on improving
operating efficiency through LeanSigma initiatives - implementing
over 150 improvements. Adjusted EBITDA margins expanded 660 basis
points over the same quarter last year. - On September 1, 2005, the
Company indicated it was exploring strategic alternatives for the
Canadian diagnostics business. The process is currently underway
and the Company remains of the view that the likely scenarios for
the business are either an outright sale or tax-efficient
distribution to shareholders. MDS will be holding a conference call
today at 10:30 am EST. This call will be webcast live at
http://www.mdsinc.com/, and will also be available in archived
format at http://www.mdsinc.com/news_present.asp after the call.
MDS Inc. has more than 8,800 highly skilled people in 27 countries.
We provide a diverse range of superior products and services to
increase our customers' speed, precision and productivity in the
drug development and disease diagnosis processes. We are a global,
values-driven health and life sciences company, recognized for our
reliability and collaborative relationships as we help create
better outcomes in the treatment of disease. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. This document contains forward-looking statements. Some
forward-looking statements may be identified by words like
"expects", "anticipates", "plans", "intends", "indicates" or
similar expressions. The statements are not a guarantee of future
performance and are inherently subject to risks and uncertainties.
The Company's actual results could differ materially from those
currently anticipated due to a number of factors, including, but
not limited to, successful integration of structural changes,
including restructuring plans, acquisitions, technical or
manufacturing or distribution issues, the competitive environment
for the Company's products, the degree of market penetration of the
Company's products, and other factors set forth in reports and
other documents filed by the Company with Canadian and US
securities regulatory authorities from time to time. MANAGEMENT'S
DISCUSSION & ANALYSIS OF OPERATING RESULTS & FINANCIAL
POSITION December 9, 2005 This section of the quarterly report
contains management's analysis of the financial performance of the
Company and its financial position and it should be read in
conjunction with the consolidated financial statements. Readers are
cautioned that management's discussion and analysis (MD&A)
contains forward-looking statements and that actual events may vary
from management's expectations. Readers are encouraged to consult
the MDS Annual Report and Annual Information Form for fiscal 2004
for additional details regarding risks affecting the business. In
our MD&A and elsewhere we refer to measures such as backlog and
other items that are not defined by generally accepted accounting
principles (GAAP). Our use of these terms may not be consistent
with the way these terms are used by others. Where possible, in
particular for earnings-based measures, we provide tables or other
information that enables readers to reconcile between such non-GAAP
measures and standard GAAP measures. While these measures are not
defined by or required by GAAP, we provide this information to
readers to help them better understand the significant events,
transactions, and trends that affect our businesses. All financial
references in this document exclude the discontinued generic
radiopharmaceuticals operations, our US laboratory operations,
certain early-stage pharmaceutical research services operations,
and our interests in Source Medical and Calgary Laboratory
Services. The discussion below is based only on our continuing
operations, unless otherwise noted. The results for all prior
periods have been restated to conform to this presentation.
Overview Revenue for the fourth quarter of fiscal 2005 was $390
million, up from $375 million over the same period last year. The
operating loss for the quarter was $34 million, versus operating
income of $11 million in the prior year. Adjusted operating income
was $49 million, a decrease of $4 million versus last year.
Adjustments include the costs of our announced restructuring
initiatives, and provisions related to long-term investments.
Adjusted earnings before interest, taxes, depreciation and
amortization (EBITDA) was $68 million at a margin of 17% compared
to $70 million and 19% last year. Adjusted EBITDA is reconciled to
operating income in a table on page 6. For the fourth quarter, the
average rate of exchange between the Canadian and US dollar was
$1.18 compared to $1.26 last year and our effective translation
rate on revenues was $1.26 versus $1.37, taking into account the
impact of our hedging program. The declining US dollar, combined
with the reduced protection of our hedge portfolio, reduced revenue
by $16 million. On a currency-adjusted basis, revenues grew 8% in
the quarter over the same period last year. On the same
currency-adjusted basis, adjusted EBITDA grew 38%. Adjusted
earnings per share from continuing operations was $0.25 for the
quarter, compared to $0.30 last year. The US dollar decline
accounts for $0.04 of the drop compared to last year and the
balance of the decline relates to decreases in operating income for
reasons described in more detail below. On September 1, 2005, we
announced our strategic plan to pursue growth in the global life
sciences market and dispose of assets that do not contribute to the
Company's area of focus. Reflecting actions intended to implement
this plan, our interests in Source Medical Corporation (Source) and
Calgary Laboratory Services (CLS) were classified as discontinued
operations in the quarter. Subsequent to the quarter-end, our
interest in Source was sold to our partner for proceeds of $79
million. Late in the quarter, the Calgary Health Region, our
partner in CLS, notified us of their intent to exercise their
option to acquire our partnership interest. We are currently in
discussions with the Region and expect to complete this transaction
by the end of March 2006. Our September 1st announcement also
outlined our intent to find an alternate ownership structure for
our Diagnostics business that realizes the maximum value for
shareholders. The detailed plan to achieve this objective is being
developed and, therefore, we have not reflected the balance of our
Diagnostics business as discontinued at this time. On December 2,
an investee company, Hemosol Corp., entered receivership. In 2003,
we wrote down the carrying value of our equity interest in this
company to nil, although we continued to provide a guarantee of the
company's bank debt. As a result of the receivership, the company's
bank requested payment by MDS under the guarantee and on December
8, we remitted $20 million to the bank. In doing so, we assumed the
loan and the senior security position held by the bank. In
conjunction with another secured lender who ranks second to us in
preference, we have agreed to provide up to $1 million of
debtor-in-possession (DIP) financing. This new funding will rank in
preference to our existing secured position. Acting with our
approval, the bankruptcy trustee has initiated a liquidation
process. The valuation of the company and its assets is highly
uncertain at this time. Although we will have the first claim on
any proceeds of the bankruptcy after the DIP financing is paid, we
are unable at this time to determine whether or not there will be
sufficient proceeds to fully repay our $20 million loan. Under
Canadian GAAP, equity accounting is required when losses sustained
by an investee create an economic exposure for the shareholder. Our
share of the operating losses sustained by Hemosol since it was
restructured in May 2004 totals $7 million and this amount has been
recorded in our fourth quarter financial statements. This amount is
included in valuation provisions and investment write-downs in our
reconciliations of adjusted EBITDA and adjusted EPS. (Tabular
amounts are in millions of Canadian dollars, except where noted.)
Summary Consolidated Fourth Full Results Quarter Year
-------------------------------------------------------------------------
2005 2004 Change 2005 2004 Change
-------------------------------------------------------------------------
Revenues $ 390 $ 375 4% $ 1,489 $ 1,479 1% Operating (loss) income
$ (34) $ 11 n/m $ 76 $ 137 (45%) Basic earnings (loss) per share $
(0.34) $ 0.06 n/m $ 0.22 $ 0.36 (39%)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
n/m (equal sign) not meaningful The following table reconciles
operating income as reported to adjusted earnings before interest,
taxes, depreciation and amortization (adjusted EBITDA): Fourth
Quarter Full Year
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Operating (loss) income - as reported $ (34) $ 11 $ 76 $ 137
Adjusted for: Restructuring charges 67 7 72 13 Valuation provisions
and investment write-downs 13 35 21 35 Other (gains) and charges 3
- 3 (18) MDS Proteomics - - - 81
-------------------------------------------------------------------------
Adjusted operating income 49 53 172 248 Depreciation and
amortization 19 17 69 58
-------------------------------------------------------------------------
Adjusted EBITDA $ 68 $ 70 $ 241 $ 306
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Details of items affecting the period-to-period comparability of
operating income and earnings per share are provided in the
following table. Fourth Quarter Full Year
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Basic Earnings (Loss) Per Share (EPS) from continuing operations -
as reported (note 3 - Consolidated Financial Statements) $ (0.21) $
0.04 $ 0.30 $ 0.44 Adjusted for: Restructuring 0.35 0.04 0.38 0.06
Valuation provisions and investment write-downs 0.10 0.22 0.13 0.22
Other (gains) and charges 0.01 - 0.01 (0.09) MDS Proteomics - - -
0.47
-------------------------------------------------------------------------
Adjusted EPS from continuing operations $ 0.25 $ 0.30 $ 0.82 $ 1.10
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Segment results Fourth Quarter 2005 2004
-------------------------------------------------------------------------
Operating Income Operating Operating Operating Revenues (Loss)
Margin Revenues Income Margin
-------------------------------------------------------------------------
Life Sciences $ 304 $ (37) (12%) $ 296 $ 9 3% Health 86 3 3% 79 2
3%
-------------------------------------------------------------------------
$ 390 $ (34) (9%) $ 375 $ 11 3%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
n/m (equal sign) not meaningful Full Year 2005 2004
-------------------------------------------------------------------------
Operating Operating Operating Income Operating Revenues Income
Margin Revenues (Loss) Margin
-------------------------------------------------------------------------
Life Sciences $ 1,154 $ 31 3% $ 1,141 $ 160 14% Health 335 45 13%
338 58 17%
-------------------------------------------------------------------------
1,489 76 5% 1,479 218 15% Proteomics - - - - (81) n/m
-------------------------------------------------------------------------
$ 1,489 $ 76 5% $ 1,479 $ 137 9%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
n/m (equal sign) not meaningful Life Sciences Review of operations
- Revenues from Life Sciences businesses for the quarter were:
Fourth Quarter 2005 2004 Change
-------------------------------------------------------------------------
Early-stage research $ 84 $ 86 (2%) Late-stage research 51 52 (2%)
-------------------------------------------------------------------------
Pharmaceutical research services 135 138 (2%)
-------------------------------------------------------------------------
Gamma sterilization 31 30 3% Nuclear medicine 56 56 - Teletherapy
systems 9 11 (18%)
-------------------------------------------------------------------------
Isotopes 96 97 (1%)
-------------------------------------------------------------------------
Analytical instruments 73 61 20%
-------------------------------------------------------------------------
$ 304 $ 296 3%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Revenue from pharmaceutical research services was $135 million, a
decline of 2% when compared to the prior year. Overall, our
pharmaceutical research revenue continues to be unfavorably
affected by the weakening of the US dollar. On a currency-adjusted
basis, revenues were up 3% compared to a strong fourth quarter in
the prior year. In early-stage business for the quarter, our
pharmacology unit continued to drive performance and was
complemented by the integration of SkeleTech Inc.'s expertise in
bone and central-nervous-system efficacy models. Our Canadian
bioanalysis business is improving; however, with significantly
lower sales levels when compared to the prior year, mainly driven
by the ongoing US Food & Drug Administration (FDA) mandated
review of bioequivalance studies. In the late-stage business,
global central labs reported 10% incremental growth compared to the
prior year, as work has ramped up on contracts previously in
backlog. The Company has a dedicated team focused on completing the
FDA mandated review at our Montreal facility. Progress on the
review is expected to accelerate as we approach completion and
integrate the learnings experienced to date, and as the complexity
of the remaining reviewable studies decreases. To ensure that we
complete these reviews on schedule, we have reduced the volume of
customer work at this facility by servicing contracts at our other
lab locations. To regain our revenue base in this business, we are
meeting with our customers to keep them advised of our findings and
to present our comprehensive scientific capabilities to bring
effective bioanalysis support to their research. Our facility in
New Orleans, which was affected by Hurricane Katrina, supports
approximately 5% of the Company's total early clinical research
beds. We assessed the damage sustained and have concluded that this
site can be reopened by mid-fiscal 2006. We expect our insurance
coverage to reimburse us for most of the losses experienced. Our
average pharmaceutical research backlog continues to expand, led by
the performance of our global central labs business. Compared to
the prior quarter and the prior year, backlog increased by 8% and
13% respectively. Quarterly Average Backlog (millions of US
dollars) -------------------------------------------------------
Fiscal 2004 - Quarter 1 $ 240 Quarter 2 265 Quarter 3 285 Quarter 4
300 Fiscal 2005 - Quarter 1 315 Quarter 2 305 Quarter 3 315 Quarter
4 340 Backlog measures are not defined by GAAP and our measurement
of backlog may vary from that used by others. While we believe that
long-term backlog trends serve as a useful metric for assessing the
growth prospects for our business, backlog is not a guarantee of
future revenues and provides no information about the timing on
which future revenue may be recorded. We report our backlog in US
dollars to reflect the underlying currency of the majority of such
contracts and, therefore, reduce the volatility that would result
from converting the measure to Canadian dollars. Revenue in our
Isotope business was up 6% on a currency-adjusted basis compared to
the prior year, although reported revenues decreased slightly, as
foreign currency impacts were only partially balanced by an
approximate 15% increase in cobalt-60 sales in the quarter. Our
order book for self-contained irradiators remained stable in the
quarter, led by our Gammacell units. Self-contained irradiators
shipped in the year increased 19% compared to the prior year. Our
teletherapy unit sales experienced softness in the quarter compared
to prior year; however, we look forward to initial shipments of the
new Equinox platform, which are scheduled for the first quarter of
2006. We also had good results from radiotherapeutic products in
the quarter. TheraSphere(R), an innovative treatment option for
liver cancer, continued to experience growth, with an approximate
80% increase in shipped doses compared to last year. In September,
we were chosen by Berlex Canada to supply Yttrium-90 Chloride
Sterile Solution (Y-90) for use with Berlex's ZEVALIN(R)
radioimmunotherapy treatment for non-Hodgkin's lymphoma. This
Canadian contract complements our supply contract with Biogen Idec
Inc. in the US. Analytical instruments revenues increased by 23% on
a currency-adjusted basis and reported revenues increased 20%
compared to the prior year. Overall shipments of analytical
instruments were up approximately 22% in the quarter, with
one-third of this increase related to our new MALDI products.
Shipments of triple quad instruments to pharmaceutical customers in
the small molecule market are strengthening, led by our API 4000
model and momentum from products launched earlier in the year,
including the API 5000 and API 3200. The recently introduced 4800
MALDI TOF/TOF has shown strong market acceptance in the proteomics
market and we have a backlog of orders at quarter-end. In addition,
our ICP/MS mass spectrometer-based products have shown encouraging
indications of a rebound to counterbalance the slower first half of
the year. Performance in this market was led by the strong showing
of our market-leading DRC II product when compared to the prior
year. Our new cell-based technology, CellKey(TM) System was
introduced at the annual Society for Biomolecular Screening
Conference held recently in Geneva, Switzerland. The CellKey(TM)
platform will offer our drug discovery customers tools to simplify
their assay design activities, address many of the bottlenecks
currently experienced within secondary screening and lead
optimization, and ultimately enable them to develop important new
medicines more rapidly. The operating loss for the Life Sciences
segment was $37 million (after the allocation of common costs) at a
margin of (12%), down from of $9 million and 3% respectively in the
prior year. Adjusted EBITDA for the segment was $46 million for the
fourth quarter of 2005 at a margin of 15%, compared with $55
million and 19% for the same period last year. The following table
reconciles operating income for the Life Sciences segment as
reported in the interim consolidated financial statements to
adjusted EBITDA: Fourth Quarter Full Year
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Operating (loss) income - as reported $ (37) $ 9 $ 31 $ 160
Adjusted for: Restructuring charges 50 6 55 8 Valuation provisions
and investment write-downs 13 25 21 25 Other (gains) and charges 3
- 3 (18)
-------------------------------------------------------------------------
Adjusted operating income 29 40 110 175 Depreciation and
amortization 17 15 61 52
-------------------------------------------------------------------------
Adjusted EBITDA $ 46 $ 55 $ 171 $ 227
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Foreign currency exposure in excess of our US dollar hedges
impacted segment operating income by $9 million in the quarter
compared to 2004. On a currency-adjusted basis, adjusted EBITDA for
the segment increased 33%. During the quarter, we determined that a
US$5 million long-term investment is impaired based on our
assessment of the carrying value of the receivable compared to the
present value of expected future cash flows. The write-off of this
asset has been reflected as an adjustment in arriving at adjusted
EBITDA for the quarter. The work MDS Pharma Services conducts in
Montreal for foreign clients is eligible for certain tax credits.
During the quarter, we increased the valuation provision relating
to these credits by approximately $3 million, to reflect our
current view of the likelihood that such claims can be collected
given current assessing practices. In our pharmaceutical research
services business, strong performance by our pharmacology business
unit, combined with a cost reduction program relating to selling
and administrative costs, made a positive contribution to operating
income. Our bioanalysis business, inclusive of the incremental FDA
review costs and adjustments to tax credits, along with timing
delays for certain global clinical development projects in our
North American business, contributed lower operating income
compared to the prior year. Our isotopes business experienced a
decrease in operating income versus the prior year, driven
primarily by currency impacts, partially balanced by the increased
shipments of cobalt-60, and the continuing growth of our
TheraSphere(R) product. The incremental change in operating income
related to analytical instruments was favorable when compared to
the prior year, resulting largely from the recovery within our
ICP/MS products, strength from our triple quad products, and solid
performance from our MALDI 4800 and other new products. Capital
expenditures - Net purchases of capital assets in Life Sciences
amounted to $37 million for the quarter compared to $32 million
last year. Included in capital expenditures for the quarter is $26
million relating to the MAPLE facility, of which $2 million
reflects capitalized interest costs. Earlier this year, we
commenced a mediation process with Atomic Energy of Canada Limited
(AECL) relating to the MAPLE facilities in an attempt to settle our
dispute with regards to commissioning delays, as well as
construction and pre-commissioning and post-commissioning operating
costs. Formal mediation proceedings were held during the fourth
quarter and the mediation process is ongoing. AECL has obtained a
renewal of the Class I Non-Power Reactor Operating License to
operate the MAPLE 1 and 2 reactors at the Chalk River Laboratories
from the Canadian Nuclear Safety Commission (CNSC), replacing the
license that was scheduled to expire on November 30, 2005. The
renewed license, which was obtained subsequent to quarter-end, is
valid until November 30, 2007 and will permit work to continue on
the commissioning of the reactors. Commissioning remains delayed as
AECL continues work to resolve outstanding technical issues,
including the positive power coefficient. We depend on the Nuclear
Research Universal (NRU) reactor, operated by AECL, for the supply
of the majority of our reactor isotopes. Following the completion
of an environment assessment in the prior quarter, the CNSC was in
a position to consider a license renewal application following a
1-day public hearing held on October 18, 2005. Subsequent to
quarter-end, the CNSC announced its decision to extend the
operating license for AECL's NRU reactor at Chalk River
Laboratories to July 31, 2006. The term of this license will now
coincide with those of other AECL Chalk River facilities. This
decision extends the operating license beyond its previously
scheduled expiry on December 31, 2005, and it will allow time for
AECL to complete a formal application for a five-year license
renewal. Segment outlook - We continue to be challenged by the weak
US dollar and will be affected even more in 2006 as our hedge
protection is diminished. To address this issue, we will focus on
achieving a more competitive cost structure. We expect to complete
our planned restructuring initiatives within this segment in fiscal
2006. We are actively capitalizing on opportunities in the
pharmaceutical research market, and we are merging the extensive
expertise found in our early stage businesses. Our most notable
success has been the creation of the Drug Development Program (DDP)
group, which offers integrated drug-development services
principally to the biotech industry. We have had good success
marketing these integrated services to our customers in the biotech
industry and we will continue to seek other synergies to provide
our customers with a comprehensive package of services. Completion
of the FDA review and marketing activities designed to rebuild our
bioanalysis business is a core priority for us going forward. In
the fourth quarter, we increased the dedicated resources assigned
to this review to ensure we meet the deadlines for completion of
the process. We are focused on resource management and deployment
in our North American global clinical development operations to
improve operational effectiveness in this business unit. Our newest
central lab operation in North Brunswick, New Jersey, is scheduled
to open in the first quarter of fiscal 2006. This new facility
increases our capacity to service North American central lab
contracts. MDS Sciex, together with its joint venture partner
Applied Biosystems, recently launched a new product line of
Tempo(TM) Liquid Chromatography (LC) systems. These systems will
provide integrated front-end solutions for researchers performing
LC/MS and LC MALDI-based experiments and are targeted to
proteomics, biotech and drug discovery markets. We are also pleased
with the market acceptance of our 4800 MALDI TOF/TOF Analyzer and
we are increasing production to ship the backlog orders. Our
manufacturing facility in Singapore was completed during the
quarter and we are currently hiring production staff for the plant.
CellKey will be the initial product manufactured at the Singapore
site and we have begun to build initial prototypes. We are on
target for commercial production to begin in the first quarter of
2006. On October 3, 2005, MDS Sciex together with its joint venture
partner Applied Biosystems announced the sale of 21 API 4000
Systems to the Centers for Disease Control and Prevention (CDC) and
several state health laboratories. These systems will be deployed
in state and local CDC labs as part of the Laboratory Response
Network and provide a validated national platform for identifying
harmful chemical agents. Our isotope business remains well
positioned for growth in 2006. Earlier this year, we negotiated an
extension to our cobalt supply agreement with Bruce Power Limited
Partnership. This new agreement has a term of 15 years. Effective
November 1, 2005, the CNSC renewed MDS Nordion's Class 1B Nuclear
Facility Operating License for a 10-year term, based on our
compliance programs and history of safe operations. This is the
first time a license for such duration has been issued. In
mid-November a competitor announced the recall of their technetium
generator product. MDS Nordion has increased its production to meet
patient needs resulting from this recall. Health Review of
operations - Revenues from the Health business in the quarter were:
Fourth Quarter 2005 2004 Change
-------------------------------------------------------------------------
Diagnostics $ 86 $ 79 9%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Diagnostic revenues increased by 9% compared to the prior year. The
Company continues to experience patient volume growth in British
Columbia (BC), reflecting ongoing demographic changes and growth in
the utilization of community laboratories. MDS is a leading
provider of laboratory services in Ontario. The existing agreement
with the Ontario Ministry of Health and Long Term Care expired on
March 31, 2005 and negotiations between the Ministry and the
Ontario Association of Medical Laboratories commenced subsequent to
the quarter-end. We continue to bill under the old agreement while
a new agreement is being negotiated. Revenue in Ontario was up
marginally compared to the prior year. The following table
reconciles operating income for the Health segment as reported in
the interim consolidated financial statements to adjusted EBITDA:
Fourth Quarter Full Year
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Operating income - as reported $ 3 $ 2 $ 45 $ 58 Adjusted for:
Restructuring charges 17 1 17 5 Valuation provisions and investment
write-downs - 10 - 10
-------------------------------------------------------------------------
Adjusted operating income 20 13 62 73 Depreciation and amortization
2 2 8 6
-------------------------------------------------------------------------
Adjusted EBITDA $ 22 $ 15 $ 70 $ 79
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Operating income for the segment was $3 million (after the
allocation of common costs) at a margin of 3%, up from $2 million
and a margin of 3% in the prior year. The increase is due mainly to
incremental BC volume and to cost management initiatives such as
the LeanSigma process improvement program initiated across our
business. Adjusted EBITDA for the segment was $22 million compared
to $15 million last year. Capital expenditures - Our diagnostics
business purchased $3 million of capital assets during the quarter
compared to $2 million for the quarter last year. The prior year
purchases were offset by the sale of assets associated with our
exit from the US laboratory business. Segment outlook - A priority
within this segment is improving operating income by the continued
execution of our LeanSigma program. We anticipate a significant
improvement in adjusted EBITDA from the reduction in headcount and
the associated process improvement initiatives. We remain committed
to delivering the same high quality service to patients and
physicians who use our services as we complete our planned
restructuring initiatives in fiscal 2006. We are actively engaged
in contract negotiations in Ontario, and expect that a new contract
will be retroactive to April 1, 2005. Restructuring In the fourth
quarter we recorded a restructuring charge of $67 million,
allocating $50 million to Life Sciences and $17 million to Health
businesses. The restructuring charges included severance of $46
million associated with an anticipated reduction in workforce of
700, of which 613 had been completed by October 31, 2005. The
remaining provision of $21 million includes capital asset
write-downs associated with abandoned IT infrastructure projects
and other charges associated with planned changes to our IT support
function and facility rationalization. Other Items For the quarter,
selling, general and administrative expenses (SG&A) were $84
million compared to $69 million last year. Spending on SG&A is
up 3% from last year as a percentage of revenues as the
restructuring had limited effect on our overhead and spending until
late in the quarter. Research and development (R&D) expenses
for the quarter were $7 million, which was a decrease of $4 million
from the prior year. In the quarter, the majority of the spending
related to new analytical instruments and our new Equinox therapy
system. The Company's tax recovery for the quarter was recorded at
a 25% effective rate (13% in the prior year). The rate is lower
than expected due principally to the fact that we were unable to
record tax benefits on the investment write-down, the Hemosol
equity loss, and on certain elements of the restructuring charge
reported in the quarter. Effective January 1, 2008 eligibility for
certain post retirement benefit plans will be reduced, and as a
result, we recorded a net curtailment gain of $4 million in the
quarter. Discontinued operations In keeping with our strategy to
focus on growth in the global life sciences market and sell assets
that do not contribute to this area of focus, Source, the
distribution operation previously within the Health segment, was
classified as a discontinued operation in the quarter. In November,
we completed the sale of our interest in Source to Cardinal Health
for proceeds of $79 million. For the quarter, net revenue and
operating income from this business were $57 million (year-to-date
$217 million) and $2 million (year-to-date $9 million),
respectively. Net income from this business was $6 million in 2005.
Within our Diagnostics business, our partner exercised its right to
purchase our interest in CLS. CLS is a medical diagnostic
laboratory that offers a range of laboratory services to the
Calgary Health Region and parts of Southern Alberta. As a result,
this interest has been classified as a discontinued operation and a
goodwill impairment charge of $16 million was recorded to reflect
our anticipated recovery from this sale. Net revenue and operating
income from this business was $18 million (year-to-date $72
million) and $1 million (year-to-date $5 million), respectively.
Net income from this business was $2 million in 2005. Certain
early-stage pharmaceutical research service businesses, comprising
our pharmaceutics, biopharmaceutics/biosafety and fermentation
operations are classified as discontinued operations. Net revenue
from these businesses was $23 million for the year with an
operating loss before shutdown costs of $9 million. The net assets
held for sale related to discontinued operations were $64 million
at quarter-end. Liquidity and capital resources Our cash position
at October 31, 2005 was $265 million, down 3% from $274 million at
July 31, 2005. Operating working capital was $84 million, a
decrease of $75 million from July 31 mainly due to elevated
accounts payables and accrued liabilities related to our
restructuring plan. Cash flow from continuing operations for the
quarter was $37 million, compared to $41 million in the fourth
quarter last year, reflecting the lower operating income. Cash used
in investing activities for continuing operations was $53 million
in the quarter, which is an increase of $49 million compared to the
prior year. Investing activities in the prior year included a net
cash inflow of $27 million resulting from the sale of certain of
our discontinued US laboratory businesses. Cash from financing
activities was $7 million compared to $12 million used in the prior
year. The prior year's spending included a significant repurchase
of shares for cancellation under our Normal Course Issuer Bid. No
shares were repurchased in the fourth quarter. The Company has a
$500 million, five-year committed, revolving credit facility which
was undrawn at October 31, 2005. The weighted average interest rate
on fixed long-term debt was 5.72% and the weighted average term to
maturity is 5 years. Financial instruments We use derivative
financial instruments to manage foreign currency and interest rate
exposure. These instruments consist of forward foreign exchange and
option contracts and interest-rate swap agreements. All derivative
instrument contracts are with banks listed on Schedule I to the
Bank Act (Canada) and the Company utilizes financial information
provided by certain Schedule I banks to determine the fair market
values of the financial instruments. At quarter-end, the net
mark-to-market value of all derivative instruments was $3 million.
Quarterly highlights Following is a summary of selected
consolidated financial information derived from the Company's
unaudited interim period consolidated financial statements for each
of the eight most recently completed quarters. This financial data
has been prepared in accordance with GAAP and prior periods have
been restated to reflect the discontinuance of the operations
discussed above. (Millions of Canadian dollars, except Earnings per
share) Fiscal 2005
-------------------------------------------------------------------------
Oct July Apr Jan
-------------------------------------------------------------------------
Net revenues $ 390 $ 370 $ 360 $ 369 Operating income (loss) (34)
26 36 48 Income (loss) from continuing operations (29) 14 25 32 Net
income (loss) $ (48) $ 19 $ 30 $ 30 Earnings (loss) per share from
continuing operations Basic $ (0.21) $ 0.10 $ 0.18 $ 0.23 Diluted $
(0.21) $ 0.10 $ 0.18 $ 0.22 Earnings (loss) per share Basic $
(0.34) $ 0.14 $ 0.21 $ 0.21 Diluted $ (0.34) $ 0.14 $ 0.21 $ 0.21
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Fiscal 2004
-------------------------------------------------------------------------
Oct July Apr Jan
-------------------------------------------------------------------------
Net revenues $ 375 $ 375 $ 369 $ 360 Operating income (loss) 11 67
- 59 Income (loss) from continuing operations 5 51 (24) 31 Net
income (loss) $ 9 $ 50 $ (36) $ 28 Earnings (loss) per share from
continuing operations Basic $ 0.03 $ 0.36 $ (0.17) $ 0.22 Diluted $
0.03 $ 0.36 $ (0.17) $ 0.22 Earnings (loss) per share Basic $ 0.06
$ 0.35 $ (0.25) $ 0.19 Diluted $ 0.06 $ 0.35 $ (0.25) $ 0.19
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Items that impact the comparability of operating income include: -
The second quarter of 2004 reflected charges related to the
write-down of our investment in MDS Proteomics to net realizable
value, partially offset by other net gains, leading to a net charge
of $62 million. - The fourth quarter of 2004 reflected
restructuring charges of $7 million and valuation provisions
totaling $35 million. - The third quarter of 2005 reflected
restructuring charges of $5 million and a write-down of licensed
technology of $8 million. - The fourth quarter of 2005 reflected
restructuring charges of $67 million and provisions related to
long-term investments of $13 million. Risks and Uncertainties To
determine the assets held for sale from the operations classified
as discontinued operations, we are required to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and, therefore, these amounts are subject to
measurement uncertainty. We adopted CICA Handbook Section 3110 -
Asset Retirement Obligations (AROs), on November 1, 2004. This
section describes how to recognize and measure liabilities related
to legal obligations related to retiring property, plant and
equipment. We have identified an asset retirement obligation of our
Isotopes business relating to decommissioning costs of a facility
located in Kanata, Ontario. We do not have sufficient information
to estimate the fair value of the asset retirement obligation. A
liability will be initially recognized in the period in which
sufficient information exists to estimate the range of potential
settlement dates that is needed to employ a present value technique
to estimate fair value. Changes in Accounting Standards In June
2005, the CICA issued Handbook Section 3831 - Non-monetary
Transactions (Section 3831) to revise and replace the current
standards on non-monetary transactions. The Company has chosen
early adoption of this policy, as permitted, effective with the
interim period commencing August 1, 2005. The new section requires
all non-monetary transactions to be measured at fair value of the
asset given up or the asset received, whichever is more reliable,
unless the transaction lacks commercial substance. The commercial
substance approach differs from the prior approach related to the
culmination of earnings process as the test for fair value
measurement. The commercial substance requirement is met when an
entity's future cash flows are expected to change significantly as
a result of the transaction. The adoption of this standard did not
have an impact on the Company's results from operations or the
financial position of the Company. CONSOLIDATED STATEMENTS OF
FINANCIAL POSITION (UNAUDITED)
-------------------------------------------------------------------------
As at October (millions of Canadian dollars) 2005 31 2004 (Restated
Note 1)
-------------------------------------------------------------------------
ASSETS Current Cash and cash equivalents $ 265 $ 296 Accounts
receivable 278 278 Unbilled revenue 115 83 Inventories 163 160
Income taxes recoverable 3 1 Current portion of future tax asset 19
14 Prepaid expenses and other 21 23 Assets held for sale (note 3)
114 51
-------------------------------------------------------------------------
978 906 Capital assets 841 785 Future tax asset 118 123 Long-term
investments and other (note 14) 159 159 Goodwill 541 548 Other
intangible assets 43 55 Assets held for sale (note 3) - 61
-------------------------------------------------------------------------
Total assets $ 2,680 $ 2,637
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and
accrued liabilities $ 353 $ 294 Deferred revenue 119 101 Income
taxes payable 28 33 Current portion of unrealized benefit of future
tax asset 16 14 Current portion of long-term debt 13 6 Liabilities
related to assets held for sale (note 3) 50 27
-------------------------------------------------------------------------
579 475 Long-term debt 455 479 Deferred revenue 26 41 Unrealized
benefit of future tax asset 64 82 Other long-term obligations 42 48
Future tax liabilities 69 58 Minority interest 20 21 Liabilities
related to assets held for sale (note 3) - 12
-------------------------------------------------------------------------
$ 1,255 $ 1,216
-------------------------------------------------------------------------
Shareholders' equity Share capital (note 2) 847 833 Retained
earnings 604 600 Currency translation adjustment (note 17) (26)
(12)
-------------------------------------------------------------------------
1,425 1,421
-------------------------------------------------------------------------
Total liabilities and shareholders' equity $ 2,680 $ 2,637
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Incorporated under the Canada Business Corporations Act. See
accompanying notes CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(SEE NOTE 3 - DISCONTINUED OPERATIONS) Three months to Year ended
October 31 October 31
-------------------------------------------------------------------------
(millions of Canadian dollars, 2005 2004 2005 2004 except per share
amounts) (Restated (Restated Note 1) Note 1)
-------------------------------------------------------------------------
Net revenues $ 390 $ 375 $ 1,489 $ 1,479 Cost of revenues (231)
(225) (912) (886) Selling, general and administration (84) (69)
(307) (267) Research and development (7) (11) (31) (38)
Restructuring (note 4) (67) (7) (72) (13) Depreciation and
amortization (19) (17) (69) (65) Other income (expense) - net (note
6) (9) (35) (17) (74) Equity earnings (loss) (note 14) (7) - (5) 1
-------------------------------------------------------------------------
Operating income (loss) (34) 11 76 137 Interest expense (5) (4)
(21) (23) Dividend and interest income 3 1 12 8
-------------------------------------------------------------------------
Income (loss) from continuing operations before income taxes and
minority interest (36) 8 67 122 Income tax recovery (expense) (note
12) 9 (1) (17) (57) Minority interest - net of tax (2) (2) (8) (2)
-------------------------------------------------------------------------
Income (loss) from continuing operations (29) 5 42 63 (Loss) income
from discontinued operations - net of tax (note 3) (19) 4 (11) (12)
-------------------------------------------------------------------------
Net income (loss) $ (48) $ 9 $ 31 $ 51
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Earnings (loss) per share (note 3) Basic $ (0.34) $ 0.06 $ 0.22 $
0.36 Diluted $ (0.34) $ 0.06 $ 0.22 $ 0.36
-------------------------------------------------------------------------
-------------------------------------------------------------------------
See accompanying notes CONSOLIDATED STATEMENTS OF RETAINED EARNINGS
Three months to Year ended October 31 October 31
-------------------------------------------------------------------------
(millions of Canadian dollars) 2005 2004 2005 2004 (Restated
(Restated Note 1) Note 1)
-------------------------------------------------------------------------
Retained earnings, beginning of period $ 657 $ 607 $ 600 $ 572 Net
income (loss) (48) 9 31 51 Repurchase of shares - (11) (8) (11)
Dividends - cash (3) (4) (14) (9) Dividends - stock (2) (1) (5) (3)
-------------------------------------------------------------------------
Retained earnings, end of period $ 604 $ 600 $ 604 $ 600
-------------------------------------------------------------------------
-------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Three months to
Year ended October 31 October 31
-------------------------------------------------------------------------
(millions of Canadian dollars) 2005 2004 2005 2004 (Restated
(Restated Note 1) Note 1)
-------------------------------------------------------------------------
Operating activities Net income (loss) $ (48) $ 9 $ 31 $ 51 Net
income (loss) from discontinued operations (19) 4 (11) (12)
-------------------------------------------------------------------------
Net income (loss) from continuing operations (29) 5 42 63 Items not
affecting current cash flow (note 9) 34 13 92 123 Changes in
non-cash working capital balances relating to operations (note 9)
32 23 1 (4)
-------------------------------------------------------------------------
Net cash provided by continuing operations 37 41 135 182 Cash
provided by (used in) discontinued operations 4 5 17 (4)
-------------------------------------------------------------------------
41 46 152 178
-------------------------------------------------------------------------
Investing activities Acquisitions (5) (10) (7) (12) Acquisitions of
tax assets - - - (19) Effect of deconsolidating MDS Proteomics - -
- (18) (Increase) decrease in deferred development charges (4) 4
(18) - Purchase of capital assets (48) (29) (126) (108) Purchase of
technology license (note 6) (1) - (1) (5) Proceeds on sale of
discontinued operations 11 27 11 35 Proceeds on sale of business
and investment - - - 2 Other (6) 4 (7) (1)
-------------------------------------------------------------------------
Net cash used in continuing investing activities (53) (4) (148)
(126) Net cash used in discontinued operations (2) (1) (5) (1)
-------------------------------------------------------------------------
(55) (5) (153) (127)
-------------------------------------------------------------------------
Financing activities Repayment of long-term debt (1) (1) (1) (2)
Increase (decrease) in deferred income and other long-term
obligations 8 3 (1) 14 Payment of cash dividends (3) (3) (14) (9)
Issuance of shares 4 8 11 18 Repurchase of shares - (17) (13) (17)
Distribution to minority interest (1) (2) (11) (11)
-------------------------------------------------------------------------
Net cash provided by (used in) continuing financing activities 7
(12) (29) (7) Net cash used in discontinued operations - - - (2)
-------------------------------------------------------------------------
7 (12) (29) (9)
-------------------------------------------------------------------------
Effect of foreign exchange rate changes on cash and cash
equivalents (2) (3) (1) (6)
-------------------------------------------------------------------------
Increase (decrease) in cash position during the period (9) 26 (31)
36 Net cash position, beginning of period 274 270 296 260
-------------------------------------------------------------------------
Net cash position, end of period $ 265 $ 296 $ 265 $ 296
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (All tabular
amounts in millions of Canadian dollars, except where noted)
-------------------------------------------------------------------------
1. Accounting Policies These consolidated financial statements of
MDS Inc. (MDS or the Company) have been prepared on a basis
consistent with the Company's annual financial statements for the
year ended October 31, 2004, except as disclosed below, and should
be read in conjunction with the accounting policies and other
disclosures in those annual financial statements. These financial
statements do not include all of the disclosures required by
generally accepted accounting principles applicable to annual
financial statements. Prior year's amounts have been restated to
reflect the results of discontinued operations. (a) Accounting
Policy Changes (i) Non-monetary Transactions In June 2005, the CICA
issued Handbook Section 3831 - Non-monetary Transactions (Section
3831) to revise and replace the current standards on non-monetary
transactions. The Company has chosen early adoption of this policy,
as permitted, effective with the interim period commencing August
1, 2005. Retroactive application is not permitted. The new section
requires all non-monetary transactions to be measured at the fair
value of the asset given up or the asset received, whichever is
more reliable, unless the transaction lacks commercial substance,
among other exceptions. The commercial substance requirement is met
when an entity's future cash flows are expected to change
significantly as a result of the transaction. Adoption of this
guideline did not have an impact on the Company's results from
operations or financial position of the Company for the period.
(ii) Asset Retirement Obligations The Company adopted CICA Handbook
Section 3110 - Asset Retirement Obligations (AROs), on November 1,
2004. This section describes how to recognize and measure
liabilities related to legal obligations of retiring property,
plant and equipment. The Company has identified an asset retirement
obligation relating to decommissioning costs of a facility located
in Kanata, Ontario. The Company does not have sufficient
information at the present time to estimate the fair value of this
obligation, and as a result has not recorded this future obligation
at October 31, 2005. (iii) Consolidation of Variable Interest
Entities In 2004, the Accounting Standards Board of the Canadian
Institute of Chartered Accountants (CICA) issued Accounting
Guideline 15, "Consolidation of Variable Interest Entities"
(AcG-15), which applies to fiscal years beginning on or after
November 1, 2004. AcG-15 establishes specific criteria to determine
if an investee is a variable interest entity and if an
equity-holder should consolidate the investee's results. This
guidance was introduced to harmonize the Canadian accounting
treatment with the United States (US) accounting treatment. The
adoption of AcG-15 has had no impact on the Company's operations
and financial position. (b) Measurement Uncertainty To determine
the assets held for sale related to those operations classified as
discontinued operations, we are required to make estimates and
assumptions that affect the reported amounts of these assets and
liabilities and, therefore, these amounts are subject to
measurement uncertainty. (c) Capital Assets On May 1, 2005, the
Company commenced the amortization of capitalized information
technology costs related to the Common Business System initiative.
These capitalized costs will be amortized on a straight-line basis
over seven years. The Company's existing policy amortizes computer
systems on a straight-line basis over a maximum of three years.
This is a change to reflect the estimated life of these new assets.
Amortization recorded in the quarter was $2 million. 2. Share
Capital The following table summarizes information on share capital
and related matters at October 31, 2005:
-------------------------------------------------------------------------
(number of shares in thousands) Outstanding Exercisable
-------------------------------------------------------------------------
Common shares 142,099 n/a Stock options 9,893 5,854
-------------------------------------------------------------------------
-------------------------------------------------------------------------
During the quarter, the Company did not repurchase any Common
shares. 3. Discontinued Operations and Assets Held for Sale The
Company has committed to a plan to divest a number of business
operations that are no longer part of the Company's strategic plan.
During the quarter, the Company's interest in Source Medical
Corporation, was classified as a discontinued operation. In
addition, in the quarter, the Company's partner in Calgary
Laboratory Services LP (CLS) exercised its right to buy out the
Company's partnership interest, and as a result, this interest has
been classified as a discontinued operation. In the prior quarter,
the Company approved a plan to divest of its Pharmaceutics,
Fermentation Biopharmaceutics/Biosafety, and in vitro Pharmacology
operations within the MDS Pharma Services business. The results of
total discontinued operations in the quarter and for the year were
as follows: Three months to Year ended October 31 October 31
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Revenues $ 82 $ 86 $ 347 $ 385
-------------------------------------------------------------------------
Income (loss) from discontinued operations - net of tax $ (19) $ 4
$ (11) $ (12)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
In accordance with Section 3475 of the CICA Handbook, long-lived
assets classified as held for sale are measured at the lower of
carrying value and fair value less costs to sell. At October 31,
2005, assets of certain operations are held for sale. The sale of
these operations is expected to occur within one year. An $18
million provision for impairment in the carrying value of goodwill
has been recorded for these operations, to reflect anticipated sale
proceeds. Assets held for sale and related liabilities as at
October 31, 2005 and 2004 comprised:
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Accounts receivable $ 32 $ 28 Inventory 24 22 Prepaid expenses 1 1
-------------------------------------------------------------------------
Current assets held for sale 57 51
-------------------------------------------------------------------------
Capital assets 31 20 Goodwill 26 41
-------------------------------------------------------------------------
57 61
-------------------------------------------------------------------------
Total assets held for sale 114 112
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Current liabilities 38 27 Other long-term obligations 12 12
-------------------------------------------------------------------------
Liabilities related to assets held for sale $ 50 $ 39
-------------------------------------------------------------------------
-------------------------------------------------------------------------
The earnings (loss) per share impact of discontinued businesses is
as follows: Three months to Year ended October 31 October 31
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Earnings (loss) per share, continuing operations $ (0.21) $ 0.04 $
0.30 $ 0.44 Earnings (loss) per share, discontinued operations
(0.13) 0.02 (0.08) (0.08)
-------------------------------------------------------------------------
Basic earnings (loss) per share $ (0.34) $ 0.06 $ 0.22 $ 0.36
-------------------------------------------------------------------------
-------------------------------------------------------------------------
4. Restructuring Reserves An analysis of the activity in the
provision through October 31, 2005 is as follows:
-------------------------------------------------------------------------
Reserve Balance at Restructuring Cumulative October Charge Drawdown
31, 2005
-------------------------------------------------------------------------
Cash Non-Cash
-------------------------------------------------------------------------
Restructuring charge at 2004 $ 13 $ (11) $ - $ 2 2005 72 (24) (9)
39
-------------------------------------------------------------------------
$ 85 $ (35) $ (9) $ 41
-------------------------------------------------------------------------
-------------------------------------------------------------------------
The Company recorded a restructuring charge of $67 million in the
fourth quarter, allocating $50 million to the Life Sciences segment
and $17 million to the Health segment. The restructuring charge
included severance of $46 million and other exit charges of $21
million. The other exit charges include a $7 million capital asset
write-down and $14 million of costs associated with abandoned
information technology infrastructure projects and other planned
changes to the Company's information technology support functions
along with costs for facility rationalization. During the quarter,
the Company made payments of $22 million in severance and other
employee related costs as part of the restructuring initiative. 5.
Earnings per Share (a) Dilution Three months to Year ended October
31 October 31
-------------------------------------------------------------------------
(number of shares in millions) 2005 2004 2005 2004
-------------------------------------------------------------------------
Net income (loss) available to Common shareholders $ (48) $ 9 $ 31
$ 51
-------------------------------------------------------------------------
Weighted average number of Common shares outstanding - basic 142
142 142 142 Impact of stock options assumed exercised - 1 - 1
-------------------------------------------------------------------------
Weighted average number of Common shares outstanding - diluted 142
143 142 143
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(b) Pro Forma Impact of Stock-Based Compensation Compensation
expense related to the fair value of stock options granted prior to
November 1, 2003 is excluded from the determination of net income
and is, instead, calculated and disclosed on a pro forma basis in
the notes to the consolidated financial statements. Compensation
expense for purposes of these pro forma disclosures is determined
in accordance with a methodology prescribed in CICA Handbook
Section 3870 "Stock-Based Compensation and Other Stock-Based
Payments". The Company used the Black-Scholes option valuation
model to estimate the fair value of options granted. For purposes
of these pro forma disclosures, the Company's net income and basic
and diluted earnings per share would have been: Three months to
Year ended October 31 October 31
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Pro forma net income (loss) available to Common shareholders $ (49)
$ 7 $ 26 $ 43 Pro forma earnings (loss) per share - basic $ (0.35)
$ 0.05 $ 0.18 $ 0.30 - diluted $ (0.35) $ 0.05 $ 0.18 $ 0.30
-------------------------------------------------------------------------
-------------------------------------------------------------------------
During the quarter, the Company granted 26,000 options (2004 -
11,000) at an average exercise price of $20.84 (2004 - $19.68).
These options have a fair value determined using the Black-Scholes
model of $7.01 per share (2004 - $6.86) based on the following
assumptions for the quarter ended October 31, 2005:
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Risk-free interest rate 3.9% 4.3% Expected dividend yield 0.68%
1.0% Expected volatility 0.321 0.342 Expected time to exercise
(years) 5.25 5.25
-------------------------------------------------------------------------
-------------------------------------------------------------------------
The Company approved in the quarter a change to the stock option
plan, which would change the vesting period of stock options
granted beginning in 2006, from five years to three years, with a
change in expiration from ten years to seven years. 6. Other Income
(Expense) - Net Three months to Year ended October 31 October 31
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Writedown of intangible assets $ - $ (15) $ - $ (15) Writedown of
long-term investments (6) (20) (6) (22) Writedown of other
long-term assets - - - (10) Gain on patent litigation - - - 14 Gain
on sale of business and other - - - 4 Gain on reorganization of MDS
Proteomics - - - 8 Write-off of purchased technology - - (8) -
Writedown of goodwill - - - (53) Unrealized loss on interest rate
swaps (note 11) (3) - (3) -
-------------------------------------------------------------------------
$ (9) $ (35) $ (17) $ (74)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
The Company recorded a provision for a US$5 million long-term
investment based on its assessment of the carrying value of the
investment to the present value of expected future cash flows. The
Company also recorded a mark-to-market loss of $3 million on the
ineffectiveness of interest rate swaps. During the prior year, the
Company recorded a provision of $15 million and $20 million to
reduce the carrying value of certain intangible assets and
long-term investments, respectively, to their estimated net
realizable values. 7. Deferred Development Charges Research costs
are expensed in the period in which they are incurred. Development
costs are expensed in the period incurred unless such costs meet
the criteria for deferral and amortization under Canadian generally
accepted accounting principles. Amortization is provided on a
straight-line basis, commencing in the year in which the product
development is completed and commercial production commences.
During the quarter, $1 million (2004 - $1 million) of capitalized
development costs were amortized and charged to income.
Year-to-date, $2 million (2004 - $3 million) was expensed. 8. Post
Employment Obligations The Company sponsors various post-employment
benefit plans including defined benefit and contribution pension
plans, retirement compensation arrangements and plans that provide
extended health care coverage to retired employees. All defined
benefit pension plans sponsored by the Company are funded plans.
Other post-employment benefits are unfunded. During the quarter,
the Company amended the terms of certain post-employment health
care benefit plans. Effective January 1, 2008, and subject to
certain transitional conditions, newly retired employees will no
longer be entitled to extended health care benefits. As a result of
the changes, the Company recorded a net curtailment gain of $4
million recorded in the quarter. Benefit costs of $1 million were
paid in the quarter (2004 - $1 million). 9. Supplementary Cash Flow
Information Non-cash items affecting net income comprise: Three
months to Year ended October 31 October 31
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Depreciation and amortization $ 19 $ 17 $ 69 $ 65 Writedown of
investments 6 20 6 22 Minority interest 2 2 11 2 Deferred income
(3) (5) (15) (17) Future income taxes (1) (18) (4) (29) Equity
earnings (loss) - net of distribution 9 (1) 12 1 Writedown of
intangible assets - 15 8 15 Writedown of capital assets 7 - 7 10
Writedown of goodwill 3 - 3 63 Gain on sale of business - (10) -
(4) Stock option compensation 1 - 3 1 Gain on sale of discontinued
operations - - (6) - Net gain on reorganization of MDS Proteomics -
- - (8) Unrealized loss on interest rate swaps 3 - 3 - Other (12)
(7) (5) 2
-------------------------------------------------------------------------
$ 34 $ 13 $ 92 $ 123
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Changes in non-cash working capital balances relating to operations
include: Three months to Year ended October 31 October 31
-------------------------------------------------------------------------
2005 2004 2005 2004
-------------------------------------------------------------------------
Accounts receivable $ (14) $ 2 $ (2) $ (52) Unbilled revenue (8) 19
(32) 4 Inventories 5 4 (9) 23 Accounts payable, accrued liabilities
and deferred revenue 57 (8) 51 (14) Income taxes payable (13) - (7)
26 Other 5 6 - 9
-------------------------------------------------------------------------
$ 32 $ 23 $ 1 $ (4)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
10. Segmented Information Three months ended Three months ended
October 31 October 31
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Life Life Sciences Health Total Sciences Health Total
-------------------------------------------------------------------------
Net revenues $ 304 $ 86 $ 390 $ 296 $ 79 $ 375 Operating income
before restructuring 13 20 33 15 3 18 Restructuring activities (50)
(17) (67) (6) (1) (7) Revenues by products and services: Medical
isotopes 96 97 Analytical equipment 73 61 Pharmaceutical research
services 135 138 Clinical laboratory services 86 79 Capital
expenditures - net 45 3 48 32 (3) 29 Depreciation and amortization
17 2 19 15 2 17
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Year ended October 31 Year ended October 31
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Life Life Sciences Health Total Sciences Health Total
-------------------------------------------------------------------------
Net revenues $ 1,154 $ 335 $ 1,489 $ 1,141 $ 338 $ 1,479 Operating
income before restructuring 86 62 148 168 63 231 Restructuring
activities (55) (17) (72) (8) (5) (13) Revenues by products and
services: Medical isotopes 325 350 Analytical equipment 286 282
Pharmaceutical research services 543 509 Clinical laboratory
services 335 338 Capital expenditures - net 118 8 126 107 1 108
Depreciation and amortization 61 8 69 52 6 58
-------------------------------------------------------------------------
-------------------------------------------------------------------------
In the prior year, operating loss for MDS Proteomics for the
year-to-date was $81 million. Depreciation and amortization for the
year-to-date was $7 million. 11. Financial Instruments As of
October 31, 2005, the Company had outstanding foreign exchange
contracts and options in place to sell up to US$139 million, and in
certain circumstances up to US$179 million, at a weighted average
exchange rate of C$1.22 maturing over the next 8 months. The
Company also had interest rate swap contracts that exchanged a
notional amount of US$80 million of debt from a fixed to a floating
interest rate. The interest rate swap contracts are designated as
hedges; however, in the fourth quarter, the hedge effectiveness
test was not met and a $3 million loss was recorded in other
expenses. The fair market value of foreign exchange options not
eligible for hedge accounting amounted to $2 million unrealized
gain during the quarter which has been recorded in selling, general
and administrative expenses. These contracts are included in
accounts payable and are marked to market each period. The carrying
amounts and fair values for all derivative financial instruments
are as follows: Three months to October 31
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Carrying Fair Carrying Fair amount Value Amount Value
-------------------------------------------------------------------------
Asset (liability) position: Currency forward and option - asset $ 4
$ 7 $ - $ 41 Currency forward and option - liabilities $ (1) $ (1)
$ (1) $ - Interest rate swap and option contracts $ (3) $ (3) $ - $
3
-------------------------------------------------------------------------
-------------------------------------------------------------------------
12. Income Taxes A reconciliation of expected income taxes to
reported income tax expense is provided below. The effective rate
for the quarter was 25% (2004 - 13%). The lower than expected tax
recovery results from our inability to recognize tax recoveries on
the investment write-down and on elements of the restructuring
charge that relate to foreign operations where full valuation
allowances exist with respect to tax assets. Three months to
October 31
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Expected income taxes expense (recovery) at MDS's 35% statutory
rate $ (13) $ 3 Increase (decrease) to tax expense as a result of:
Benefit of tax losses previously not recognized (4) (3) Investment
write-downs 5 4 Restructuring relating to certain foreign
jurisdictions 6 - Other (3) (3)
-------------------------------------------------------------------------
Reported income tax expense (recovery) $ (9) $ 1
-------------------------------------------------------------------------
-------------------------------------------------------------------------
13. Acquisitions In the quarter, the Company acquired SkeleTech
inc., a therapeutically focused contract research organization
providing pre-clinical discovery and development services in bone
and central nervous systems biologies, for consideration of US$6
million. The purchase agreement includes a provision for contingent
consideration of US$2 million, payable to the vendors if certain
profitability levels are attained in fiscal 2006. Any additional
purchase price that becomes payable under the terms of the earn-out
provision will be recorded when the amount of the payment becomes
measurable. This acquisition has been accounted for using the
purchase method. The purchase price has been allocated to the net
assets acquired based on management's best estimate of fair values.
The total cost of the acquisition has been allocated as follows:
-------------------------------------------------------------------------
2005
-------------------------------------------------------------------------
Working capital $ (1) Capital assets and other 1 Goodwill 6
-------------------------------------------------------------------------
Total cash consideration $ 6
-------------------------------------------------------------------------
-------------------------------------------------------------------------
14. Guarantees In 2003, the Company undertook to guarantee a $20
million bank loan on behalf of an investee, Hemosol Corp. (the
"Borrower"), in exchange for warrants in the Borrower. This loan
was secured by a fixed and floating charge over all assets of the
Borrower. Under the guarantee, MDS was subrogated to and took an
assignment of the rights and remedies of the bank under the loan.
In the second quarter of 2005, the term of the Borrower's credit
facility was extended to May 25, 2007 and the guarantee was
extended from June 20, 2005 to June 30, 2007. As consideration for
the extension, the Company received warrants to purchase up to 2.75
million common shares (687,500 post-consolidation) of the Borrower
at an exercise price of $0.84 per share ($3.36 per share
post-consolidation) with a term of five years from the date of
issuance. The Company believed that the fair value of the units was
nominal, and accordingly ascribed no value to these units. The
Company now accounts for its investment in the Borrower using the
equity method of accounting. The Company's share of the investee's
losses exceeds the carrying amount of the investment, and a $7
million equity loss adjustment was recorded in the quarter.
Subsequent to quarter-end, the Borrower entered receivership. As a
result of the receivership, the Borrower's bank has requested
payment by the Company of the amounts due on the bank loan. On
December 8, 2005, the Company remitted $20 million to the bank and,
in turn, assumed the loan and the senior security position held by
the bank. Due to measurement uncertainty, the Company is not able
to determine if sufficient proceeds from the sale of the assets of
the Borrower will be available to recover the Company's investment.
15. Contractual Obligations The Company entered into a new cobalt
supply agreement with Bruce Power LP, which became effective
January 1, 2005. The agreement has a term of 14 years. 16.
Subsequent Events Subsequent to the quarter-end, the Company sold
its interest in Source Medical Corporation for gross proceeds of
$79 million. 17. Comparative Figures Certain figures for the
previous year have been reclassified to conform to the current
year's financial statement presentation. In addition, segmented
information for 2004 has been restated to reflect the discontinued
operations reported. During the quarter, the Company changed its
method of translating certain components of the net investment in
self-sustaining foreign subsidiaries, which resulted in a credit to
Goodwill and a debit to Cumulative Translation Adjustment in the
amount of $83 million. The prior period has been adjusted to
reflect this change. DATASOURCE: MDS Inc. CONTACT: For further MDS
information: Investor & Media Contact: Sharon Mathers,
Vice-President, Investor Relations, (416) 675-6777 x 2695,
Copyright